Johnson & Johnson's second-quarter results might look bad on the surface--the strong dollar dragged down overall sales by 7.9%--but even without that hit, the top line grew by just 1.7%. Its fast-growing pharma business, which has been making up for shortfalls elsewhere in the company for some time, faltered because of collapsing Olysio sales.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
J&J's IL-23 blocker came through in a Phase IIb psoriasis study, with one of the top doses clearing symptoms of the disease in 86% of patients. Easily beating out the placebo response, the top psoriasis contender--which is facing off against a lineup of competing remedies in late-stage development--also beat out Humira in the study.
The search for an HIV vaccine has been long and difficult, but researchers from Johnson & Johnson, Harvard and other groups may have made a leap. J&J's Janssen reported encouraging results Thursday from its preclinical trial of an HIV vaccine in rhesus monkeys. Encouraging enough for the company to sponsor human studies--the first time a Big Pharma is doing so in the HIV space.
In response to slower sales and increased competition, medical device makers are starting to offer hospitals and patients in the U.S. better guarantees on their products if they don't perform as promised.
With the second quarter now past, number-crunchers are trying to anticipate the next round of pharma earnings. And for Johnson & Johnson, the word is that its fast-growing drugs will keep on delivering year-over-year growth--with one key exception.
Price checks by India's National Pharmaceutical Pricing Authority on certain orthopedic implants have once again raised hackles by companies concerned they are being swept up in a law that was not meant for their industry, Business Standard reports.
A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.